Neurocrine: funding the expanded pipeline
Neurocrine’s Q2 outlook puts GAAP R&D at $1.275B–$1.325B and discusses clinical-program and milestone costs. Research expense is distinct from acquired-IPR&D presentation.
Neurocrine Biosciences / NBIXPublic biotechR&D-spendingDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- The Q2 financial outlook is historical and may have been updated.
Primary evidence
Reporting date unconfirmed — research candidate
Neurocrine Q2 2026 results and financial guidanceCompany source
Potential outcome market
Will Neurocrine 2026 GAAP R&D expense exceed $1.3 billion?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.